The use of homologous virus in the haemagglutination-inhibition assay after vaccination with Newcastle disease virus strain La Sota or Clone30 leads to an over estimation of protective serum antibody titres

被引:11
作者
Maas, RA
Oei, HL
Kemper, S
Koch, G
Visser, L
机构
[1] DLO, ID, Dept State Qual Control & Standardizat, NL-8200 AB Lelystad, Netherlands
[2] DLO, ID, Dept Avian Virol, NL-8200 AB Lelystad, Netherlands
关键词
D O I
10.1080/03079459808419394
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
We evaluated the influence of the use of the Newcastle disease virus (NDV)-strains Lister and La Sota in the haemagglutination inhibition (HI) assay for the measurement of antibody titres after NDV vaccination. The use of the homologous La Sota antigen in the HT assay after Clone30 and La Sota vaccination of SPF-chickens, resulted in significantly higher titres than the use of the heterologous Lister virus, The mean difference was 1.4 on a log(2) scale (2.6-fold). A significant difference was also found in virus neutralization (VN) assays. The virus strain in the HI or VN test did not influence the resulting titres after Ulster vaccination, When HI antibody titres after vaccination were related to VN titres measured with virulent Herts NDV or to survival after virulent challenge, it was found that the use of La Sota antigen in the HI assay after vaccination with Clone30 or La Sota resulted in an overestimation of protective serum antibody titres. Also in commercially derived White Leghorns vaccinated with Clone30, significantly higher HI titres were obtained when La Sota antigen was used in the HI test. Our data have direct implications for potency testing of inactivated vaccines as the European Pharmacopeia does not prescribe the antigen to be used in the HI test.
引用
收藏
页码:625 / 631
页数:7
相关论文
共 20 条
[1]   NEWCASTLE-DISEASE IN COUNTRIES OF THE EUROPEAN UNION [J].
ALEXANDER, DJ .
AVIAN PATHOLOGY, 1995, 24 (01) :3-10
[2]   USE OF ANTIBODIES TO PURIFIED NEWCASTLE-DISEASE VIRUS GLYCOPROTEINS FOR STRAIN COMPARISONS AND CHARACTERIZATIONS [J].
AVERY, RJ ;
NIVEN, J .
INFECTION AND IMMUNITY, 1979, 26 (03) :795-801
[3]   HEMAGGLUTINATING AND FUSOGENIC ACTIVITIES OF NEWCASTLE-DISEASE VIRUS - STUDIES ON RECEPTOR-BINDING SPECIFICITY AND PH-INDUCED CONFORMATIONAL-CHANGES [J].
COUCEIRO, ESS ;
COUCEIRO, JNSS ;
CABRAL, MC .
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1995, 90 (04) :515-520
[4]   NEWCASTLE-DISEASE VACCINE (LASOTA) STRAIN SPECIFIC MONOCLONAL-ANTIBODY [J].
ERDEI, J ;
ERDEI, J ;
BACHIR, K ;
KALETA, EF ;
SHORTRIDGE, KF ;
LOMNICZI, B .
ARCHIVES OF VIROLOGY, 1987, 96 (3-4) :265-269
[5]  
*EUR PHARM, 1997, MON
[6]   SEROLOGY-BASED POTENCY TEST FOR INACTIVATED NEWCASTLE-DISEASE VACCINES [J].
GODDARD, RD ;
NICHOLAS, RAJ ;
LUFF, PR .
VACCINE, 1988, 6 (06) :530-532
[7]   STRUCTURAL FEATURES UNIQUE TO EACH OF THE 3 ANTIGENIC SITES ON THE HEMAGGLUTININ NEURAMINIDASE PROTEIN OF NEWCASTLE-DISEASE VIRUS [J].
GOTOH, B ;
SAKAGUCHI, T ;
NISHIKAWA, K ;
INOCENCIO, NM ;
HAMAGUCHI, M ;
TOYODA, T ;
NAGAI, Y .
VIROLOGY, 1988, 163 (01) :174-182
[8]   FUNCTIONAL AND NEUTRALIZATION PROFILE OF 7 OVERLAPPING ANTIGENIC SITES ON THE HN GLYCOPROTEIN OF NEWCASTLE-DISEASE VIRUS - MONOCLONAL-ANTIBODIES TO SOME SITES PREVENT VIRAL ATTACHMENT [J].
IORIO, RM ;
GLICKMAN, RL ;
RIEL, AM ;
SHEEHAN, JP ;
BRATT, MA .
VIRUS RESEARCH, 1989, 13 (03) :245-261
[9]   NEUTRALIZATION MAP OF THE HEMAGGLUTININ-NEURAMINIDASE GLYCOPROTEIN OF NEWCASTLE-DISEASE VIRUS - DOMAINS RECOGNIZED BY MONOCLONAL-ANTIBODIES THAT PREVENT RECEPTOR RECOGNITION [J].
IORIO, RM ;
SYDDALL, RJ ;
SHEEHAN, JP ;
BRATT, MA ;
GLICKMAN, RL ;
RIEL, AM .
JOURNAL OF VIROLOGY, 1991, 65 (09) :4999-5006
[10]   CHARACTERIZATION OF A BATTERY OF MONOCLONAL-ANTIBODIES FOR DIFFERENTIATION OF NEWCASTLE-DISEASE VIRUS AND PIGEON PARAMYXOVIRUS-1 STRAINS [J].
LANA, DP ;
SNYDER, DB ;
KING, DJ ;
MARQUARDT, WW .
AVIAN DISEASES, 1988, 32 (02) :273-281